更正：绝经前后中国女性HR+/HER2-晚期乳腺癌的初始ribociclib加内分泌治疗：一项2期随机研究的初步结果

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2024-09-14 DOI:10.1002/cam4.70233

{"title":"更正：绝经前后中国女性HR+/HER2-晚期乳腺癌的初始ribociclib加内分泌治疗：一项2期随机研究的初步结果","authors":"","doi":"10.1002/cam4.70233","DOIUrl":null,"url":null,"abstract":"Shao Z, et al., Cancer Med. 2024 Aug;13(15):e7408. https://doi.org/10.1002/cam4.7408. PMID: 39136200; PMCID: PMC11320080We requested post-publication to add the following line after the first line in the acknowledgment section:We also thank DMC chair Prof. Xichun Hu, DMC member Prof. Jin Zhang, Prof. Shusen Wang, Prof. Renbing Liu, and Prof. Chen Yao for their contributions to the trial.We apologize for this error.","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70233","citationCount":"0","resultStr":"{\"title\":\"Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study\",\"authors\":\"\",\"doi\":\"10.1002/cam4.70233\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Shao Z, et al., Cancer Med. 2024 Aug;13(15):e7408. https://doi.org/10.1002/cam4.7408. PMID: 39136200; PMCID: PMC11320080We requested post-publication to add the following line after the first line in the acknowledgment section:We also thank DMC chair Prof. Xichun Hu, DMC member Prof. Jin Zhang, Prof. Shusen Wang, Prof. Renbing Liu, and Prof. Chen Yao for their contributions to the trial.We apologize for this error.\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70233\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70233\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70233","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Shao Z, et al., Cancer Med.2024 Aug;13(15):e7408. https://doi.org/10.1002/cam4.7408.PMID: 39136200; PMCID: PMC11320080我们请求在发表后在致谢部分的第一行后添加以下内容：我们还要感谢DMC主席胡锡纯教授、DMC成员张进教授、王树森教授、刘仁兵教授和姚晨教授为该试验做出的贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study

Shao Z, et al., Cancer Med. 2024 Aug;13(15):e7408. https://doi.org/10.1002/cam4.7408. PMID: 39136200; PMCID: PMC11320080

We requested post-publication to add the following line after the first line in the acknowledgment section:

We also thank DMC chair Prof. Xichun Hu, DMC member Prof. Jin Zhang, Prof. Shusen Wang, Prof. Renbing Liu, and Prof. Chen Yao for their contributions to the trial.

We apologize for this error.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.